Researchers at the University of Arizona are investigating a novel approach to prevent asthma in young children by examining the potential of a specific medication to bolster the developing immune system.
Asthma, a condition characterized by the lungs overreacting to triggers such as viruses, pollen, or exercise, could see a new preventative strategy with the study of Broncho-Vaxom.This medication is already widely prescribed in Europe and Latin America.
“We obtained authorization from the FDA to use this product in children aged 6 to 18 months by mouth, giving it to them for two years to see if after they stop this product, they would have less asthma than other children,” stated Dr. Fernando Martinez, director of UA’s Asthma and Airway Disease research Center.
Dr. Martinez explained that Broncho-Vaxom is being administered to infants as part of a placebo-controlled study. The decision to begin with infants stems from the desire to intervene before symptoms manifest, as asthma often develops very early in life.
The study is slated to conclude by the end of the year, with findings anticipated to be presented at the 2026 American Academy of Asthma, Allergy and Immunology Conference.
Asthma impacts approximately 4.5 million children across the United States, presenting critically important challenges for affected families. “This is very traumatic for the families.So what we would like is for people not to have asthma, not to have to take medicines every day, not to develop the disease so they can have a perfectly healthy life,” Martinez added.
Share your thoughts on this groundbreaking research in the comments below.Subscribe to world Today News for more updates on health innovations.
